Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Laboratory science

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Tau neurofibrillary tangles (NFTs) in the presence of amyloid-β (Aβ) plaques are required for the diagnosis of Alzheimer's Disease (AD) and closely track with cognitive impairment, yet cognitively normal aged individuals frequently exhibit NFTs arising from tau seed accumulation. This may suggest that not all tau species are equally pathogenic and raises the question of whether unidentified tau modifications augment tau seeding activity and neurodegeneration in AD. We investigated how biochemical modifications of tau relate to clinicopathological outcomes in a cohort of 38 patients with Braak-matched AD neuropathologic change (ADNC) or primary age-related tauopathy (PART), a 3R/4R tauopathy with identical tau filament core structure to ADNC but with little to no Aβ deposition. We comprehensively measured tau histologic density, seeding activity using real-time quaking induced conversion (RT-QuIC) seed amplification assays, and select post-translational modifications (PTMs) (i.e. pT217, pS202/T205, & C-terminal epitopes) in hippocampus and neocortex. Even in cases without overt neocortical tau neuropathology, substantial hippocampal and neocortical tau seeding occurred in both PART and ADNC and predicted region-specific cognitive performance and longitudinal decline. Notably, tau seeding and PTM profiles were associated with Aβ neuritic plaque density and differentiated ADNC from PART in neocortex. Our data indicate that tau seed modifications meaningfully relate to disease trajectory, potentially explaining the more severe cognitive dysfunction observed in late-stage AD versus PART.

What this study adds

Evidence grade: Early

This is a case-control study of 38 participants. In 38 patients with Braak-matched Alzheimer's disease neuropathologic change or primary age-related tauopathy, tau seeding and post-translational modification profiles were associated with amyloid-beta neuritic plaque density and differentiated the two conditions in neocortex. Its stated limit: Both PART and ADNC show asymmetric neuropathology, especially early, and the standard brain-bank practice of fixing one hemisphere and freezing the other is a known limitation that may attenuate the strength of associations.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Browne, D. F., Smirnov, D. S., Coughlin, D. G., Peng, I., Standke, H. G., Kim, Y., et al. (2025). Early Alzheimer's Disease with frequent neuritic plaques harbors neocortical tau seeds distinct from primary age-related tauopathy. Nature Communications. https://doi.org/10.1038/s41467-025-56469-7

Vancouver

Browne DF, Smirnov DS, Coughlin DG, Peng I, Standke HG, Kim Y, et al. Early Alzheimer's Disease with frequent neuritic plaques harbors neocortical tau seeds distinct from primary age-related tauopathy. Nature Communications. 2025. doi:10.1038/s41467-025-56469-7. PMID: 39984462.

BibTeX

@article{browne2025-39984462,
  author  = {Browne, D. F. and Smirnov, D. S. and Coughlin, D. G. and Peng, I. and Standke, H. G. and Kim, Y. and Pizzo, D. P. and Unapanta, A. and Andreasson, T. and Hiniker, A. and Kraus, A.},
  title   = {{Early Alzheimer's Disease with frequent neuritic plaques harbors neocortical tau seeds distinct from primary age-related tauopathy}},
  journal = {Nature Communications},
  year    = {2025},
  doi     = {10.1038/s41467-025-56469-7},
  pmid    = {39984462},
  url     = {https://doi.org/10.1038/s41467-025-56469-7}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 11 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

In 38 patients with Braak-matched Alzheimer's disease neuropathologic change or primary age-related tauopathy, tau seeding and post-translational modification profiles were associated with amyloid-beta neuritic plaque density and differentiated the two conditions in neocortex. The data suggest tau seed modifications relate to disease trajectory and may explain more severe cognitive dysfunction in late-stage Alzheimer's disease, but no treatment is tested.

Study details

Limitations

Both PART and ADNC show asymmetric neuropathology, especially early, and the standard brain-bank practice of fixing one hemisphere and freezing the other is a known limitation that may attenuate the strength of associations.

How this study scored 61/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 6 of 12; Strength of evidence 2 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 60 of the 98 points it could be judged on, which is 61 of 100. Total 61 of 100.60 of the 98 points we could judge = 61 of 100

Published in a leading specialty journal, and it is a case-control study. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 60 of the 98 points we could judge it on, which is 61 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Nature Communications)
Journal's citation record 4 / 4 Nature Communications: journal h-index 747 (OpenAlex, 2026-10-29)
Study design 6 / 12 A case-control study
Strength of evidence 2 / 5 Rated “early” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 38 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 15 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 5.0 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 8.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 2 / 4 Cited 15 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Allison Kraus: h-index 25 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39984462)
Free to read — / 2 Access not recorded — left out of this score
Points 60 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 60 of the 98 points we could judge it on is 61 out of 100.
Total 61 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Laboratory science from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Laboratory science

See all studies in Laboratory science →